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Abstract
Background: Psychostimulants such as methylphenidate and modafinil are increasingly used by healthy people for cognitive 
enhancement purposes, whereas the acute effect of 3,4-methylenedioxymethamphetamine (ecstasy) on cognitive functioning 
in healthy subjects remains unclear. This study directly compared the acute effects of methylphenidate, modafinil, and 
3,4-methylenedioxymethamphetamine on the neural mechanisms underlying response inhibition in healthy subjects.
Methods: Using a double-blind, within-subject, placebo-controlled, cross-over design, methylphenidate, modafinil, and 
3,4-methylenedioxymethamphetamine were administrated to 21 healthy subjects while performing a go/no-go event-related 
functional magnetic resonance imaging task to assess brain activation during motor response inhibition.
Results: Relative to placebo, methylphenidate and modafinil but not 3,4-methylenedioxymethamphetamine improved 
inhibitory performance. Methylphenidate significantly increased activation in the right middle frontal gyrus, middle/superior 
temporal gyrus, inferior parietal lobule, presupplementary motor area, and anterior cingulate cortex compared with placebo. 
Methylphenidate also induced significantly higher activation in the anterior cingulate cortex and presupplementary motor 
area and relative to modafinil. Relative to placebo, modafinil significantly increased activation in the right middle frontal 
gyrus and superior/inferior parietal lobule, while 3,4-methylenedioxymethamphetamine significantly increased activation in 
the right middle/inferior frontal gyrus and superior parietal lobule.
Conclusions: Direct comparison of methylphenidate, modafinil, and 3,4-methylenedioxymethamphetamine revealed broad 
recruitment of fronto-parietal regions but specific effects of methylphenidate on middle/superior temporal gyrus, anterior 
cingulate cortex, and presupplementary motor area activation, suggesting dissociable modulations of response inhibition 
networks and potentially the superiority of methylphenidate in the enhancement of cognitive performance in healthy subjects.
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Introduction
Successful response inhibition is essential to process and 
integrate incoming perceptual information in a flexible fash-
ion (Bari and Robbins, 2013). Such a trial-by-trial adjustment 
of information processing is important for adapting ongoing 
behavior according to prevailing conditions in the respective 
environment. The inability to inhibit responses has been linked 
to several prevalent disorders, including obsessive-compulsive 
disorder, autism, and attention-deficit/hyperactivity disorder 
(ADHD). Response inhibition, as often operationalized by the go/
no-go task (Bari and Robbins, 2013), has been associated with 
significant activation in a widespread network of brain regions 
including the superior, middle (MFG), and inferior frontal gyrus 
(IFG), inferior parietal lobule, striato-thalamic regions, and the 
presupplementary motor area (pre-SMA) / anterior cingulate 
cortex (ACC) (Simmonds et al., 2008; Swick et al., 2011). Although 
a complex neural circuit is involved in response inhibition, it 
is the activation in the right IFG that allows the inhibition of a 
prepotent motor response, a conclusion that is corroborated by 
connectivity and causality studies (Aron et al., 2014). Hence, the 
assessment of IFG activation helps to study the neuropharma-
cological mechanisms of response inhibition and to test the effi-
cacy of potentially novel medications for disorders associated 
with impaired response inhibition.
A previous meta-analysis of stop-signal and go/no-go tasks 
showed that ADHD patients reveal reduced activation in the 
right IFG, SMA, and ACC, as well as striato-thalamic areas during 
response inhibition (Hart et  al., 2013). It has been shown that 
methylphenidate (MPH), the most frequently prescribed drug 
for the treatment of ADHD (Briars and Todd, 2016), normalized 
fronto-temporal activation (including right IFG) during response 
inhibition in ADHD patients during the stop-signal (Rubia et al., 
2014). The therapeutic effect of MPH is likely mediated through 
increases in extracellular levels of norepinephrine (NE) and 
dopamine (DA) in prefronto-striatal brain regions (Hannestad 
et  al., 2010), both neurotransmitters critically involved in 
response inhibition (Bari and Robbins, 2013). Acute MPH admin-
istration also improved response inhibition during the stop-sig-
nal task (Nandam et al., 2011) and increased activation in the 
ACC, right IFG, superior temporal gyrus, caudate and left MFG, 
and left angular gyrus during the go/no-go task in healthy sub-
jects (Nandam et al., 2014). In contrast, however, it has also been 
shown that MPH reduced activation in the right IFG/ insula to 
infrequent stimuli associated with successful inhibition, failed 
inhibition, and attentional capture during stop-signal tasks in 
healthy subjects (Pauls et al., 2012). Interestingly, another study 
found that MPH increased activation in the putamen only dur-
ing inhibition errors but not during successful inhibition and 
only in the go/no-go but not stop-signal task (Costa et al., 2013).
Modafinil, licensed for the treatment of narcolepsy, shift-
work disorder, and obstructive sleep apnea (Erman et al., 2007; 
Sheng et  al., 2013), has also emerged as a possible agent to 
improve cognition. Both MPH and modafinil are being increas-
ingly used as cognitive enhancers for nonmedical reasons 
(Sahakian et  al., 2015). Modafinil produced cognitive enhanc-
ing effects and decreased stop-signal reaction time in healthy 
adults (Turner et al., 2003) and improved cognitive functioning in 
people with ADHD (Turner et al., 2004). Acute administration of 
modafinil to healthy subjects improved task performance dur-
ing the stop-signal task but did not modulate brain activation 
(Schmaal et al., 2013). Modafinil is a weak inhibitor of DA and 
NE transporter and has additional effects on the brain GABA, 
glutamate, and orexin systems (Minzenberg and Carter, 2008), 
although the precise neuropharmacological mode of action of 
modafinil remains unclear.
Response inhibition is also strongly associated with integ-
rity of the serotonergic (5-HT) system in humans and animals 
(Eagle et al., 2007). A reduction of 5-HT has been linked to impul-
sive, suicidal, and aggressive behavior, whereas high levels of 
5-HT have been shown to decrease impulsive behavior (Pattij 
and Vanderschuren, 2008; Fitzgerald, 2011). A  previous study 
demonstrated improved response inhibition in a stop-signal 
task after acute administration of 3,4-methylenedioxymetham-
phetamine (MDMA, ecstasy) in healthy subjects compared with 
placebo (Ramaekers and Kuypers, 2006). Given that MDMA acts 
primarily by releasing 5-HT from presynaptic terminals (Liechti 
and Vollenweider, 2000; Hysek et  al., 2011, 2012), the authors 
suggested a possible link with 5-HT neurotransmission for this 
effect (Ramaekers and Kuypers, 2006). However, this MDMA-
induced improvement in response inhibition is in contrast to 
another study reporting increased reaction times in a stop-
signal task after MDMA administration to healthy controls (van 
Wel et al., 2012).
The present study directly compares for the first time the 
acute effects of MPH, modafinil, and MDMA on the behavioral 
and neural correlates of response inhibition in healthy controls. 
It thereby sought to elucidate the neural mechanisms under-
lying MPH’s and modafinil’s cognitive enhancing effect and to 
provide further insights into the neuropharmacological base of 
response inhibition. Using a within-subject, placebo-controlled, 
cross-over design, MPH, modafinil, and MDMA were admin-
istrated to healthy subjects while performing a fMRI go/no-go 
task. Our a priori hypothesis was that MPH and modafinil but 
not MDMA would improve inhibitory performance during the 
go/no-go task compared with placebo. We further predicted that 
MPH and modafinil but not MDMA would increase brain activa-
tion (in particular IFG activation) during response inhibition.
Methods
The study was conducted in accordance with the Declaration 
of Helsinki and International Conference on Harmonization 
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Guidelines in Good Clinical Practice and approved by the local 
Ethics Committee and Swiss Agency for Therapeutic Products 
(Swissmedic). The administration of MDMA to healthy subjects 
was authorized by the Swiss Federal Office for Public Health, 
Bern, Switzerland. The study was registered at ClinicalTrials.gov 
(NCT01951508). After receiving a written and oral description of 
the aim of this study, all participants gave written informed con-
sent statements before inclusion.
Participants and Study Design
We recruited a group of 24 healthy subjects by word of mouth 
or an advertisement placed on the web market platform of the 
University of Basel. Subjects were excluded due to the following 
reasons: (1) chronic or acute medical condition including clini-
cally relevant abnormality in physical exam, laboratory values, 
or ECG (in particular: seizures or a cardiac or neurological dis-
order); (2) current or previous psychotic or major affective disor-
der; (3) prior illicit drug use more than 5 times (except occasional 
use of THC-containing products) or any time within the previous 
2  months; (4) pregnant or nursing women; (5) participation in 
another clinical trial (currently or within the last 30 days); (6) use 
of medications that are contraindicated or otherwise interfere 
with the effects of the study medications (monoamine oxidase 
inhibitors, antidepressants, sedatives, etc.); and (7) tobacco smok-
ing (regularly > 10 cigarettes/d). Previous drug use is reported in 
supplementary Table 1. Subjects were asked to abstain from any 
illicit drug use including cannabis during the study, and drug 
tests were performed during screening and randomly before test 
sessions. There were no positive urine tests for stimulants, opi-
oids, THC, or hallucinogens and therefore no exclusions from the 
study. Subjects were also asked to abstain from excessive alco-
hol consumption between test sessions and in particular to limit 
their use to one glass on the day before the test sessions.
Using a double-blind, placebo-controlled, randomized, 
within-subject design, participants received MPH (60  mg), 
modafinil (600 mg), MDMA (125 mg), and placebo in a counter-
balanced order. The wash-out period between sessions was at 
least 7 days. Three participants did not complete all 4 go/no-go 
sessions, resulting in a final sample of 21 subjects (10 men, 11 
women; mean age: 23.6 ± 2.8, range: 21–30).
MDMA was administered in a single absolute dose of 
125 mg corresponding to a relatively high dose of (mean ± SD) 
1.9 ± 0.3 mg/kg body weight. This dose of MDMA is in the high 
range of the doses typically used in clinical research (Kirkpatrick 
et  al., 2014, 2015; Kuypers et  al., 2017) and is within the dose 
range that is used recreationally (Brunt et al., 2012). MPH was 
administered in a single relatively high dose of 60 mg as done in 
previous studies (Martin et al., 1971; Korostenskaja et al., 2008). 
The subjective and cardiostimulant effects of this dose have pre-
viously been assessed on the same tests (Hysek et al., 2014) and 
have also been statistically compared with a lower dose of 40 mg 
(Schmid et al., 2014). The doses of MDMA and MPH were expected 
to be equivalent regarding their cardiovascular stimulant effects 
(Hysek et al., 2014). The therapeutic starting dose of modafinil is 
100 mg and common doses are 400 mg/d. In this study, modafinil 
was administered in a single high dose of 600 mg. The goal was 
to use high single doses of all substances to maximize the sub-
jective drug effects and reach responses close to Emax.
Drug Administration
Each of the 4 test sessions lasted 7 hours. Subjects arrived at the 
laboratory at 8:45 am. MPH, modafinil, MDMA, or placebo was 
administered orally at 9:45 am. fMRI scanning was performed 
between 11:15 am and 12:15 pm during the expected drug peak 
effects (Wong et al., 1998; Hysek et al., 2014; Schmid et al., 2014). 
The sessions ended at 3:45 pm. Additional study findings are 
reported elsewhere (Dolder et al., 2017).
Psychometric Assessment
The Adjective Mood Rating Scale (AMRS) (Janke, 1978) was 
used to assess subjective drug effects directly before (75 min-
utes posttreatment) and after (150 minutes posttreatment) the 
fMRI scanning took place. We averaged the values of the 75 and 
150 min posttreatment assessments to best relate the subjec-
tive drug effects to the go/no-go task. In this study, we focused 
on the AMRS subscales related to cognitive control functioning 
such as activation, concentration, and performance-related acti-
vation. Performance-related activation is the sum of activation 
and concentration ratings.
The Go/No-Go Task
Ninety minutes after drug administration, all patients under-
went an event-related go/no-go fMRI paradigm that was 
conducted with jittered inter-stimulus intervals (ISIs) and 
incorporated infrequently presented oddball stimuli to opti-
mize statistical efficiency, that is, the accuracy with which the 
hemodynamic response to different stimuli can be estimated for 
a given amount of imaging time (Dale, 1999). The task is a well-
validated paradigm used in previous fMRI studies (Rubia et al., 
2006; Schmitz et  al., 2006; Smith et  al., 2006; Borgwardt et  al., 
2008; Lawrence et al., 2009; Atakan et al., 2013; Schmidt et al., 
2013; Bhattacharyya et al., 2014, 2015; Daly et al., 2014), requir-
ing either the execution or the inhibition of a motor response, 
depending on the visual presentation of the stimuli. The basic 
go task is a choice reaction time paradigm, in which arrows 
point either to the left or to the right side for 500 milliseconds, 
with a mean ISI of 1800 milliseconds (jitter range: 1600–2000 
milliseconds). During go trials, subjects were instructed to press 
a left or right response button according to the direction of the 
arrow. In 11% of the trials, arrows pointing upward appeared. 
During these so-called no-go trials, participants were required 
to inhibit their motor response. During another 11% of the trials, 
arrows pointing left or right at a 23° angle were presented, and 
subjects were told to respond to these in the same way as for 
go stimuli (even though they pointed obliquely). These oddball 
stimuli were used to control for novelty effects associated with 
the low frequency and different orientation of the no-go relative 
to the go trials (stimulus-driven attention allocation). In total, 
there were 24 no-go, 160 go, and 24 oddball trials, with task dura-
tion of approximately 6 minutes.
Analyses of Inhibitory Performance and Subjective 
Feelings of Cognitive Controls
Behavioral task performance was evaluated by the probability 
of inhibition, correct number of go trials, and reaction time to 
go trials. Treatment differences in task performance and the 4 
AMRS items were examined using a repeated-measures ANOVA 
with treatment as within-subject factor. Where the ANOVA null 
hypothesis of equal means was rejected, we used posthoc tests 
(Bonferroni).
fMRI Image Acquisition and Analysis
Scanning was performed on a 3T scanner (Siemens Magnetom 
Verio; Siemens Healthcare) using an interleaved T2*-weighted 
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echo planar imaging (EPI) sequence with 2.5-second repetition 
time, 28-millisecond echo time, a matrix size of 76 x 76, and 38 
slices with 0.5-mm interslice gap, providing a resolution of 3 x 3 
x 3 mm3 and a field of view of 228 x 228 cm2. In total, 160 volumes 
were acquired.
EPIs were analyzed using an event-related design with SPM12 
(www.fil.ion.ucl.ac.uk/spm). During preprocessing, images were 
realigned to the first image in the series, spatially normalized 
to the Montreal Neurological Institute template, and smoothed 
with a Gaussian kernel of 8 mm full half-width maximum. All 
images underwent visual inspection, and participants with a 
high number of severely corrupted images and/or gross artefacts 
were excluded (none). Additionally, all images were checked for 
movement artefacts, and all scans with more than 3 mm devia-
tion from the previous scan in any dimension, resulting in cor-
rupted volumes, were excluded and replaced with the average 
of the neighboring volumes (4 volumes were replaced in total, 
all after MDMA administration). Subjects with >10% corrupted 
volumes were excluded (none). There were no movement dif-
ferences across treatment in any dimension (supplementary 
Table 2).
Voxel-wise maximum likelihood parameter estimates were 
calculated during the first-level analysis using the general lin-
ear model. Our design matrix included an autoregressive AR(1) 
model of serial correlations and a high-pass filter with a cut-
off of 128 seconds. Onset times for go, no-go, and oddball trials 
across all 4 treatments were convolved with a canonical hemo-
dynamic response function, and motion parameters acquired 
during the realignment procedure were added to the individ-
ual design matrix as multiple regressors. Five subject-specific 
contrast images were generated per participant: 4 images rep-
resenting response inhibition controlled for the attentional 
oddball effect due to the low frequency occurrence of no-go tri-
als (no-go vs. oddball trials) for each treatment (placebo, MPH, 
modafinil, MDMA); and 1 average image for response inhibition 
over all treatments (to compute the effect of task). A 1-sample 
t test was performed to examine whole brain activation dur-
ing response inhibition across all treatments (effect of task). 
Treatment differences were examined using a within-subject 
ANOVA design. To control for drug order effects, we included 
drug order as regressor of no interest into the ANOVA analysis. 
According to recent recommendations on cluster-extent based 
thresholding in fMRI analyses (Woo et  al., 2014), significance 
was assessed at a cluster-level threshold of P < .05 family-wise 
error corrected across the whole brain, using an uncorrected 
cluster-forming threshold of P < .001 with an extent threshold 
of 20 voxels.
Results
Subjective Feelings of Cognitive Performance
All stimulants overall significantly increased scores on acti-
vation as revealed by a significant main effect of treatment (F 
(3, 18) = 3.622, P = .033). Posthoc testing showed a significantly 
enhanced activation following MPH administration relative to 
placebo (P = .018), while no other differences between drugs 
were found (Figure 1). We found no main effect of treatment for 
concentration (F (3, 18) = 1.953, P = .157; Figure 1). Furthermore, 
there was a main effect of treatment for performance-related 
activation (F (3, 18) = 3.323, P = .043). Bonferroni posthoc testing 
yielded that this effect was driven by a significant enhancement 
of performance-related activation after MPH intake relative to 
placebo (P = .022) (Figure 1).
Behavioral Task Performance
We found a significant treatment effect for probability of inhibi-
tion (F (3, 18) = 4.24, P =  .020), indicating a generally improved 
inhibitory performance after simulant exposures. Posthoc anal-
ysis revealed that MPH (P  =  .012) and modafinil (P  =  .038) but 
not MDMA improved inhibitory performance relative to placebo 
(Figure 2A).
Stimulants significantly increased the responses to go trials 
(F (3, 18) = 7.30, P = .002). The number of correct go trials was 
higher following MPH (P  =  .003) and modafinil (P  =  .005) but 
not MDMA administration compared with placebo (Figure 2B). 
There was also a significant treatment effect for reaction times 
(F (3, 18) = 6.19, P = .004), indicating faster reactions in response 
to go trials after stimulant intake. Relative to placebo, reaction 
times were significantly lower after MPH exposure (P  =  .003) 
(Figure 2C).
Brain Activation during Response Inhibition
Effect of Task
Combined treatment maps revealed significant activation in 
frontal, parietal, temporal, striato-thalamic, and cerebellar brain 
regions during response inhibition (supplementary Table 3).
Treatment Effects during Response Inhibition
Brain activation during response inhibition significantly differed 
across treatments in the right MFG, superior/inferior parietal 
lobule and supramarginal gyrus, and pre-SMA (supplementary 
Figure 1; supplementary Table 4).
Posthoc testing revealed that MPH increased brain acti-
vation relative to placebo in the right MFG, inferior parietal 
lobule, supramarginal gyrus, middle/superior temporal gyrus, 
as well as in the right ACC and pre-SMA (Figure  3A; supple-
mentary Table 5). Compared with placebo, modafinil increased 
activation in the right MFG and superior and inferior parietal 
lobule, whereas MDMA increased activation in the right MFG 
(extending to the IFG), superior parietal lobule, and angular 
gyrus (Figure  3B-C; supplementary Table  5). Finally, ACC and 
pre-SMA activation was significantly higher after MPH com-
pared with modafinil administration (Figure  3D; supplemen-
tary Table 5).
Figure 1. Subjective ratings of cognitive control (activation, concentration, and 
performance-related activation) after substance administration. (*) reflects sig-
nificant differences compared to placebo. Error bars represent standard errors.
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Discussion
To the best of our knowledge, this is the first within-subject 
study directly comparing the acute effects of MPH, modafinil, 
and MDMA on the behavioral and neural correlates of response 
inhibition in healthy controls. We found that both MPH and 
modafinil enhanced inhibitory performance with a concomi-
tant increase in fronto-parietal activation. In addition, MPH was 
dissociable from modafinil and placebo in terms of its modula-
tion of ACC and pre-SMA activation. Finally, MDMA did not alter 
Figure 2. Task performance expressed as (A) probability of inhibition, (B) number of correct responses to go trials, and (C) reaction times to go trials after substance 
administration. (*) significant differences in task performance between substances. Error bars represent standard errors.
Figure 3. Significant differences in brain activation during response inhibition between (A) MPH and placebo, (B) modafinil and placebo, (C) MDMA and placebo, and 
(D) MPH and modafinil. Image is displayed at a cluster-forming threshold of P < .001 uncorrected, with an extent threshold of 20 voxels. The color bar indicates t values.
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inhibitory performance but was associated with alteration in 
fronto-parietal activation relative to placebo.
Besides their use for treating symptoms in ADHD patients 
(Briars and Todd, 2016), psychostimulants such as MPH and 
modafinil are being increasingly used by healthy people for cog-
nitive enhancement purposes mainly to produce alertness and 
enhance professional performance (Sahakian et  al., 2015). In 
the present study, both MPH and modafinil improved inhibitory 
performance in healthy people during the go/no-go task relative 
to placebo, supporting the view of beneficial effect of MPH and 
modafinil on cognitive performance in healthy people (Sahakian 
and Morein-Zamir, 2015). These findings are in line with other 
studies in healthy subjects demonstrating improved response 
inhibition (stop-signal reaction time) after acute MPH (Nandam 
et al., 2011) and modafinil (Turner et al., 2003; Schmaal et al., 2013).
Consistent with another go/no-go study in healthy subjects 
(Nandam et al., 2014), we found that MPH increased activation 
in right MFG, superior temporal gyrus, and ACC compared with 
placebo. MPH also increased activation in the right supramar-
ginal gyrus, inferior parietal lobule, middle temporal gyrus, and 
pre-SMA in this study. Although MPH also increases DA levels in 
prefrontal regions, the observed increase in prefrontal activation 
here is likely mediated via NE neurotransmission (Chamberlain 
and Sahakian, 2007), given that in frontal regions MPH increases 
NE more than DA via reuptake inhibition of NE transporter 
(Hannestad et al., 2010). This corresponds with a previous fMRI 
go/no-go study, which showed that atomoxetine, a selective NE 
reuptake inhibitor increased fronto-temporal brain activation in 
healthy people (Chamberlain et al., 2009).
In the present study, acute modafinil administration also 
increased activation in the right MFG and superior/ inferior 
parietal lobule compared with placebo. Modafinil is a nonam-
phetamine psychostimulant that elevates synaptic NE and DA 
levels in prefrontal regions (de Saint Hilaire et al., 2001). Many 
of modafinil’s cognitive and behavioral effects are mediated by 
adrenergic receptors (Minzenberg and Carter, 2008). A previous 
fMRI study in healthy humans reported that modafinil increased 
activation in the locus coeruleus and prefrontal cortex and the 
functional coupling between these regions during a cognitive 
control task (Minzenberg et al., 2008). Another study in rats dem-
onstrated that response inhibition in the stop-signal paradigm 
improved after modafinil and MPH administration, and these 
effects were not blocked by concurrent DA receptor antagonism, 
nor was response inhibition affected by DA receptor antagonism 
per se (Eagle et  al., 2007). Furthermore, direct infusion of the 
alpha-2 adrenoceptor antagonist yohimbine into the prefrontal 
cortex of nonhuman primates impaired inhibitory control on a 
go/no-go paradigm and was associated with increased locomo-
tor hyperactivity (Ma et al., 2005). Together, these findings sug-
gest that increased prefrontal activation after modafinil and 
MPH administration is more likely mediated by increased levels 
of NE than DA. Such an interpretation resonates with previous 
works suggesting a key role for prefrontal NE neurotransmis-
sion in the inhibition of an already initiated response, whereas 
DA appears to modulate motor readiness for both inhibition and 
activation, potentially at the level of the striatum (Chamberlain 
and Sahakian, 2007; Bari and Robbins, 2013).
Party drugs such as MDMA are consumed recreationally for 
their acute mood- and social-enhancing effects. It has been 
shown that the acute psychological and physiological effects of 
MDMA in humans are mediated via an increase in 5-HT (Liechti 
et al., 2000, 2001; Liechti and Vollenweider, 2000). Acute MDMA 
administration has been shown to increase impulse control 
when 5-HT levels are high (Ramaekers and Kuypers, 2006). In 
the present study, acute MDMA administration did not affect 
inhibitory performance relative to placebo during the go/no-go 
task. This finding supports previous evidence that pharmaco-
logical manipulations of the 5-HT system have no detectable 
behavioral effects on response inhibition (Chamberlain and 
Sahakian, 2007). Although behavioral no-go effects of 5-HT 
interventions are often mild or absent in humans, neuroimaging 
has revealed altered activation in frontal regions. For instance, 
reduced IFG activation during the go/no-go task has been found 
after acute tryptophan depletion in healthy volunteers (Rubia 
et al., 2005), while the selective 5-HT reuptake inhibitor escit-
alopram increased activation in the ACC and middle frontal 
and temporal gyrus during successful inhibition during a stop-
change paradigm (extension of stop-signal task) (Drueke et al., 
2013). Along this line, citalopram also increased activation in the 
right dorsolateral prefrontal cortex and middle frontal gyrus in 
healthy subjects during the go/no-go task (Del-Ben et al., 2005). 
Consistent with these findings, we found increased activation 
in the right MFG/ IFG after MDMA administration compared 
with placebo and also in the superior parietal lobule and angu-
lar gyrus. However, we cannot be certain whether this effect 
is mediated directly via a MDMA-induced increase in 5-HT or 
rather NE (Hysek et al., 2012). This interpretation fits with find-
ings from a recent study showing that the psychotropic effects of 
MDMA are not only mediated through 5-HT but also NE release 
(Hysek et al., 2011, 2012). However, although there were indica-
tions of improvements in all behavioral measures after MDMA 
intake in this study, the MDMA-induced increase in right IFG/ 
MFG and inferior parietal lobule activation may not have been 
sufficient to improve inhibitory performance. The lack of effect 
on inhibitory performance following MDMA administration 
despite neural changes is intriguing. It supports previous stud-
ies using acute tryptophan depletion in healthy controls that 
failed to find effects on inhibitory control during the go/no-go 
task in healthy subjects (Rubia et al., 2005; Lamar et al., 2009). 
We can speculate that potential noradrenergic MDMA effects on 
inhibitory performance are offset by its serotonergic effects.
Finally, we found that acute MPH administration increased 
ACC and pre-SMA activation compared with modafinil. It has 
been proposed that the ACC is functionally interconnected with 
the basal ganglia and prefrontal cortex to form a key node of 
the response inhibition network (Aron et  al., 2014). While the 
prefrontal cortex maintains goals and the basal ganglia sup-
press irrelevant motor responses, the ACC may detect response 
conflict (Aron et  al., 2014). Therefore, ACC activation during 
response inhibition might reflect the conflict that occurs when 
2 incompatible responses, such as whether to go or stop, are 
both compelling (MacDonald et al., 2000). Consistent with such 
an interpretation, a previous work showed that MPH acutely 
increased activation in the ACC and superior frontal gyrus for 
failed inhibitions during a stop-signal task, but only after con-
trolling for attentional capture (Pauls et al., 2012). Furthermore, 
MPH also increased activation in the putamen during inhibition 
errors in the go/no-go task (Costa et al., 2013). Based on these 
findings and having in mind that we also controlled our imag-
ing results for effects of stimulus-driven attention allocation, 
our finding suggests that MPH induced higher ACC activation in 
response to failed inhibitions than modafinil. ACC functioning 
has been associated with DA (Jocham and Ullsperger, 2009; Ko 
et al., 2009) and NE signalling (Aston-Jones et al., 2000; Aston-
Jones and Cohen, 2005). Therefore, the MPH effect on ACC acti-
vation relative to modafinil is perhaps caused by differential 
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modulation of DA pathways that project from the ventral teg-
mental (Williams and Goldman-Rakic, 1998) and of NE projec-
tions from the locus coeruleus (Aston-Jones et  al., 2000). We 
might speculate that increased prefrontal activation after MPH 
is due to a higher blockade of DA and NE transporter relative 
to modafinil, leading to increased levels of DA and NE. In other 
words, the MPH-induced increase in prefrontal activation rela-
tive to modafinil is probably mediated through differential 
dynamic effects of MPH and modafinil on DA and NE in the pre-
frontal cortex (Rowley et al., 2014).
Some limitations of our study merit comment. Although we 
used a well-established paradigm from previous fMRI studies 
(Rubia et al., 2006; Schmitz et al., 2006; Borgwardt et al., 2008; 
Lawrence et al., 2009; Schmidt et al., 2013; Bhattacharyya et al., 
2014, 2015; Daly et  al., 2014), we were not able to disentangle 
neural activation in response to successful vs. failed inhibitions 
in the present study due to the modest number of no-go trials. 
The small number of inhibition trials (i.e., no-go trials) also lim-
its the functional relevance of our behavioral results, albeit MPH 
and modafinil significantly increased the probability of inhibi-
tion. In this regard, it is also possible that the modest number of 
inhibition trials may explain the lack of alteration after MDMA 
administration. Future studies with a higher number of no-go 
trials are required to address these points. Furthermore, we can-
not exclude effects on cerebral vasoactivity induced by the drugs 
(Honey and Bullmore, 2004), which might have confounded 
our fMRI results. For instance, it is possible that the effect of 
modafinil and MPH on MFG, ACC, and pre-SMA activation might 
be driven by their effects on regional cerebral blood flow in the 
same regions (Udo de Haes et al., 2007; Joo et al., 2008).
In conclusion, this study shows a common recruitment of 
fronto-parietal regions after MPH, modafinil, and MDMA but spe-
cific effects of MPH on middle/superior temporal gyrus, anterior 
cingulate cortex, and presupplementary motor area activation, sug-
gesting dissociable modulations of response inhibition networks 
and potentially the superiority of MPH in the enhancement of 
cognitive performance in healthy subjects. These effects are likely 
mediated via increased extracellular concentrations of NE, which 
may have reached the highest levels after MPH administration.
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